Early‐Stage Formulation Considerations

Robert W. Lee1, Mark Mitchnick1

1 Particle Sciences, Inc., a Lubrizol LifeSciences Company, Pennsylvania, Bethlehem
Publication Name:  Current Protocols in Chemical Biology
Unit Number:   
DOI:  10.1002/cpch.32
Online Posting Date:  December, 2017
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library

Abstract

When a drug candidate—i.e., a new chemical entity (NCE) or new molecular entity (NME)—is discovered, there is a requirement to identify a vehicle for in vitro and/or in vivo evaluation to assess the activity and/or toxicity of the compound (here we refer to the biologically active compound as the active pharmaceutical ingredient: API). Ideally, this vehicle will not impart any biological activity or any toxicity that would mask or confound the effects of the API. At this early stage in development, and given the high attrition rates of drug candidates in discovery, it does not make sense to fully characterize the API—speed and cost are generally the driving factors. This chapter provides guidance for the development of early‐stage test articles (i.e., drug products containing APIs intended to be used for the in vitro and/or in vivo evaluation) and not necessarily formulations that are intended to progress into clinical evaluation. © 2017 by John Wiley & Sons, Inc.

Keywords: drug discovery; new chemical entity; new molecular entity; preformulation; test article; vehicle

     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Table of Contents

  • Introduction and Purpose
  • Preformulation and Analytical Characterization Considerations
  • Considering the Biopharmaceutical Classification System for Formulation Evaluation
  • Formulation Approach—Strategic
  • Formulation Approach—Tactical
  • Concluding Remarks
  • Literature Cited
  • Figures
  • Tables
     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Materials

GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Figures

Videos

Literature Cited

Literature Cited
  Carstensen, J. T. (1998). Pharmaceutical Preformulation. Valley Stream, NY: Technomic Publishing Co., Inc.
  Chaurasia, G. (2016). A review on pharmaceutical preformulation studies in formulation and development of new drug molecules. International Journal of Pharmaceutical Sciences and Research, 7(6), 2313–2320. doi: 10.13040/IJPSR.0975‐8232.7(6).2313‐20.
  Diehl, K.‐H., Hull, R., Morton, D., Pfister, R., Rabemampianina, Y., Smith, D., … van de Vorstenbosch, C. (2001). A good practice guide to the administration of substances and removal of blood, including routes and volumes. Journal of Applied Toxicology, 21, 15–23. doi: 10.1002/jat.727.
  Gaisford, S., & Saunders, M. (2012). Basic principles of preformulation studies. In Essentials of Pharmaceutical Preformulation (Chapter 1). Chichester, UK: John Wiley & Sons, Ltd. doi: 10.1002/9781118423226.ch1.
  Ku, M. S. (2008). Use of the biopharmaceutical classification system in early drug development. The AAPS Journal, 10(1), 208–212. doi: 10.1208/s12248‐008‐9020‐0.
  Lee, R. W. (2005). Case study: Development and scale‐up of NanoCrystal® particles. In D. J. Burgess (Ed.), Injectable Dispersed Systems: Formulation, Processing and Performance, Vol. 149 (pp. 355–370). Boca Raton, FL: Taylor & Francis.
  Lee, R. W., Shaw, J. M., McShane, J., Wood, R. W., & Shenoy, D. B. (2008). Particle size reduction. In R. Liu (Ed.), Water‐Insoluble Drug Formulations, (2nd ed., pp. 467–498). Boca Raton, FL: CRC Press.
  Loxley, A. (2012). Devices and implant systems by hot‐melt extrusion. In D. Douroumis (Ed.), Hot‐Melt Extrusion: Pharmaceutical Applications (pp. 301–321). Chichester, UK: John Wiley & Sons, Ltd. doi: 10.1002/9780470711415.ch14.
  Mitchnick, M., & Lee, R. W. (2012). Comments on biopharmaceutical classification system and formulation development. Life Science Connect, Guest Column, Retrieved from https://www.pharmaceuticalonline.com/doc/comment-biopharmaceutical-classification-formulation-development-0001.
  Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., … Weir, A. (2015). An Analysis of the attrition of drug candidates from four major pharmaceutical companies. Nature Reviews Drug Discovery, 14, 475–486. doi: 10.1038/nrd4609.
  Wu, C.‐Y., & Benet, L. Z. (2005). Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharmaceutical Research, 22(1), 11–23. doi: 10.1007/s11095‐004‐9004‐4.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library